Kimal PLC is delighted to announce its new strategic partnership with Marizyme, Inc. for DuraGraft®, the Company’s flagship product.
DuraGraft is an intraoperative vascular graft storage and flushing solution that prevents ischaemia reperfusion injury, which is the basis for vein graft disease; and Kimal will have exclusive distribution rights in the UK.
This partnership will bring together Marizyme’s expertise in developing innovative medical device technologies with Kimal’s extensive distribution network and specialised market knowledge. Together, the Companies will bring DuraGraft into the market more efficiently and effectively, creating a wider network of healthcare providers and patients that can benefit from DuraGraft during CABG surgery procedures.
Matt Press, Kimal CEO, says, “We are delighted to announce our partnership with Marizyme to launch DuraGraft in the UK. Kimal’s Vision is to provide treatment solutions that support best-in-class patient outcomes, and we believe that DuraGraft represents the best elements of this Vision. We therefore are extremely excited about bringing this innovative technology to coronary artery bypass graft procedures in the UK, and specifically launching a product that improves the outcomes for those patients undergoing this life-saving procedure.”
Dave Barthel, Marizyme’s CEO, says “We are thrilled to be partnering with Kimal PLC as we look to expand DuraGraft into new markets. This strategic partnership strengthens the position of both our Company and product and continues to validate DuraGraft as a leading solution for use in CABG surgery procedures. Kimal PLC is an expert in their field, and their distribution network and knowledge will prove invaluable as we continue to ramp up commercialisation. Marizyme will continue to look for strategic partnerships that strength the distribution and commercialisation capabilities of DuraGraft.”
Founded in 1964, Kimal is an innovative manufacturer of customised procedure packs and vascular access devices to clinical departments in over 70 countries worldwide. The Company manufactures and distributes over 2 million procedure packs and vascular access devices across its international operations, which sees over 500 people employed across six countries.
Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialisation of medical technologies that improve patient health outcomes. Marizyme is commercialising its flagship product, DuraGraft, and developing its pipeline of medical technologies to address critical market gaps and offer transformative solutions for coronary artery bypass graft (CABG) surgery, pet health, and chronic kidney disease (CKD).
To learn more, please contact info@marizyme.com or visit www.marizyme.com.
Kimal Contact:
Kathryn McKenzie-Rowan, Group Corporate Communications Manager
marcomms@marizyme.com
This story was written by Medilink Midlands Patron, Kimal. To find out more about Medilink Midlands patronage, click here.
